Keywords: Actelion, Opsumit, PAH, MAA accepted

Actelion filing for EU approval of Opsumit accepted

Article | 23 November 2012

Switzerland-based Actelion (SIX: ATLN) says that it has submitted a Marketing Authorisation Application (MAA) for Opsumit (macitentan) for the treatment ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Actelion

Go to company listing

Related Drugs

macitentan

Opsumit

Go to drug listing